

Radium-223 is a well tolerated and safe treatment for metastatic castration resistant prostate cancer (mCRPC): real world data from a single cancer center



Guy's and St Thomas' 
NHS Foundation Trust

Nikolaos Tsoukalas¹, Maria Saigí Morgu¹, Celia Mills², Alexandra Dudek¹, Athanasios Pouptsis¹, Christos Nikolaou¹, Deborah Enting¹, Simon Chowdhury¹, Val Lewington², Sarah Rudman¹

¹Guy's and St Thomas' NHS Foundation Trust, Oncology Department, London, UK

²Guy's and St Thomas' NHS Foundation Trust, Nuclear Medicine Department, London, UK

Introduction

Radium-223 is an alpha emitter that selectively targets bone metastases. It has been approved for the treatment of CRPC with bone metastases and without visceral involvement.

Objectives

We present real world data for the first two years of Radium-223 administration at Guy's Hospital.

Methods

CRPC patients with bone metastases received Radium-223 for a period of two years. 50kBq/kg Radium-223 was given intravenously every 28 days for 6 cycles.

Results

60 patients with median age 75 years (49-86) were studied. ECOG PS was 0-1 in 55% and 2 in 45%. 80% had > 6 bone metastases while 20% had a superscan. 63.3% had bone pain WHO score 2 or more and 30% were receiving concurrent bisphosphonates. The majority (71.7%) had received 2 or more lines of prior treatments. 49 (81.7%) had finished treatment while the remaining 11 patients continue Radium-223. 22 of 49 (45%) completed all 6 cycles of treatment, while disease progression

was the main cause for treatment interruption (26 patients) and 1 stopped due to toxicity.

Patients with 2 or less previous lines of treatment had an increased likelihood of completing 5 or 6 cycles of therapy ($p=0.013$). There was a trend for patients PS 0-1 to complete 5-6 cycles of Radium-223 compared to patients PS 2 ($p=0.79$). Treatment was well tolerated and safe. Most of adverse events were grade 1-2 while incidence of grade 3-4 events was less than 3% (anaemia).

Conclusions

Radium-223 is well tolerated and safe treatment. Optimal patient selection remains crucial in order to ensure effective treatment delivery.

Acknowledgments

We would like to acknowledge the Hellenic Society of Medical Oncology (HeSMO) for support.

HESMO

means

Hellenic Society of Medical
Oncology